Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986299 |
| Synonyms | |
| Therapy Description |
BMS-986299 is an NLRP3 agonist that induces IL8 release to activate natural killer (NK) cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986299 | BMS986299|BMS 986299 | BMS-986299 is an NLRP3 agonist that induces IL8 release to activate natural killer (NK) cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03444753 | Phase I | BMS-986299 + Ipilimumab + Nivolumab BMS-986299 | An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed | Terminated | USA | 0 |